Visible light-activatable cyclodextrin-conjugates for the efficient delivery of nitric oxide with fluorescent reporter and their inclusion complexes with betaxolol. (1st April 2021)

• Record Type: Journal Article
• Authors: Seggio, Mimimorena; Payamifar, Sara; Fraix, Aurore; Kalydi, Eszter; Kasal, Petr; Catanzano, Ovidio; Conte, Claudia; Quaglia, Fabiana; Sortino, Salvatore
• Is Part Of: New journal of chemistry. Volume 45:Number 19(2021)
• Page Start: 8449
• Page End: 8455
• Publication Date: 2021-04-01
• Subjects: Chemistry -- Periodicals; Chimie -- Périodiques; 540
• DOI: 10.1039/d1nj00039j
• Languages: English
• ISSNs: 1144-0546

Abstract

Abstract : Water-soluble β-CD conjugates release NO with high performances with blue and green light, liberate a fluorescent co-products useful for the real-time monitoring of the NO concentration and encapsulate additional guests within the hydrophobic cavity. Abstract : This contribution reports the design, synthesis, photochemical properties and drug inclusion capability of two novel β-cyclodextrin (βCD) conjugates, βCD-NBFNO1 and βCD-NBFNO2, covalently integrating an N-nitroso amino-nitro-benzofurazan in the primary and secondary hydroxyl rims of the βCD scaffold, respectively through flexible spacers of different length. Both βCD conjugates are water-soluble and release nitric oxide (NO) under the input of either blue or green light, with quantum yields Φ NO (blue) = 0.13, 0.31 and Φ NO (green) = 0.007, 0.013 respectively, the former representing the largest values ever reported for nonmetal-containing NO donors activatable by visible light. The good contrast between the fluorescence green emission of the chromogenic moiety after and before the NO release permits the easy and in real-time quantification of the amount of NO generated, without the addition of external fluorescent agents. Despite the presence of the appendages, these βCD derivatives are also able to complex betaxolol, a β-blocker drug widely used for the reduction of the intraocular pressure, with binding constants K b = 500 ± 50 and 1100 ± 100 M −1, respectively, without affecting the photochemical performances. In view of the well-known vasodilator properties of NO, the present βCD derivatives represent intriguing candidates for biopharmaceutical research studies addressed to combined therapeutic ocular applications.